Chronic alcohol consumption upregulates ceramide synthase 6 in hepatic lipid droplets and zone 3 hepatocytes of mice and humans
AASLD LiverLearning®, Amanke Oranu, 194828
Liver-brain axis in alcoholic liver disease: Chronic alcohol induces recruitment of peripheral macrophages with different inflammatory gene expression profile into the liver and brain
AASLD LiverLearning®, Patrick Lowe, 194829
Roles of designated hepatologists on treatment of chronic hepatitis C patients with directly-acting antivirals: Evidences based on nation-wide, real-world database in Japan
AASLD LiverLearning®, Naohiko Masaki, 195085
Impact of metabolic risk factors in non-cirrhotic patients with alcoholic liver disease
AASLD LiverLearning®, Mads Israelsen, 194830
The Real-World Israeli Experience of Treating Chronic Hepatitis C (CHC), Genotype 1 (GT1) and Genotype 4 (GT4) Patients with Advanced Fibrosis with Elbasvir\ Grazoprevir: A Large Multi-Center Cohort.
AASLD LiverLearning®, Eli Zuckerman, 195086
Metabolic Reprogramming In Patients With Alcoholic Hepatitis: Identification Of The Polyol Pathway As Potential Target For Therapy
AASLD LiverLearning®, Veronica Massey, 194844
Occurrence of new of hepatocellular carcinoma in patients with hepatitis C treated with all oral direct-acting anti-virals
AASLD LiverLearning®, Gabriela Kuftinec, 195100
Targeted liver metabolomics reveals a role for CCL2 in arginine metabolism and glutathione generation in a model of alcoholic liver injury
AASLD LiverLearning®, Pranoti Mandrekar, 194845
Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r + Dasabuvir 8 Weeks: Results from a Spanish Real World Cohort (Hepa-C)
AASLD LiverLearning®, Marc Puigvehí, 195101
Hepatocyte apoptosis is linked to decreased TET1 and 5-hydroxymethylcytosine in rat alcoholic liver disease
AASLD LiverLearning®, Jack Wands, 194846
Weight based ribavirin with sofosbuvir and daclatasvir for 12 weeks for patients with Genotype 3 Hepatitis C and cirrhosis: An analysis of efficacy and long-term clinical outcomes.
AASLD LiverLearning®, Chiara Mazzarelli, 195102
Single cell gene expression analysis identifies a chronic alcohol-mediated shift in the distribution of hepatocyte molecular states after partial hepatectomy
AASLD LiverLearning®, Rajanikanth Vadigepalli, 194860
The impact of direct acting antivirals (DAAs) in patients with decompensated liver disease (DLD) due to chronic hepatitis C (CHC). HERACLIS - a multicenter Greek real world study
AASLD LiverLearning®, Spilios Manolakopoulos, 195116
Role of 13C-Octanoate Breath Test for non-invasive evaluation of Alcoholic Steatohepatitis
AASLD LiverLearning®, Carmen-Georgeta Fierbinteanu Braticevici, 194861
Direct Acting Antiviral HCV Treatment Influence Lactate and Glucose Levels
AASLD LiverLearning®, Curtis Cooper, 195117
Mice with myeloid-specific deletion of StARD1 develop acute-on-chronic alcoholic steatohepatitis
AASLD LiverLearning®, Jose Fernandez-Checa, 194862
Safety and effectiveness of treatment of hepatitis C virus with direct acting antivirals in patients with solid organ transplantation
AASLD LiverLearning®, Marlina Mansour, 195118
Welcome and Overview / Aims of the Workshop
AASLD LiverLearning®, Clifford Steer, 202042
Session I Moderator
AASLD LiverLearning®, Keith Jerome, 202043
Caspase 1-dependent cleavage of the Rab7 trafficking adaptor RILP links inflammasome activation to increased exosome secretion in inflammatory liver diseases
AASLD LiverLearning®, Ann Wozniak, 194876
Long-term improvement of liver function parameters after IFN-free therapy of advanced HCV- associated liver cirrhosis - Results from the German Hepatitis C-Registry (DHC-R)
AASLD LiverLearning®, Katja Deterding, 195132
Yap1 Activation Induces TGF-β Signaling and Epithelial-to-Mesenchymal Transition (EMT) in Regenerating Hepatocytes After Partial Hepatectomy
AASLD LiverLearning®, Seh-Hoon Oh, 194877
Safety and Efficacy of Treatment with Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients with Severe Renal Impairment
AASLD LiverLearning®, Shampa De-Oertel, 195133
Lipid droplet homeostasis is crucial for the establishment of polarity in collagen sandwich-cultured hepatocytes.
AASLD LiverLearning®, Sun Woo Sophie Kang, 194878
Treatment-failure to direct antiviral regimens in real world: frequency, patient characteristics and rescue therapy - Results from the German Hepatitis C-Registry (DHC-R)
AASLD LiverLearning®, Christoph Sarrazin, 195134
Hepatic Stellate Cell-Induced Cytotoxicity in Liver Cancer Cells: Special Role of Apoptosis Inducing Factor (AIF)
AASLD LiverLearning®, Ehsan Fayazzadeh, 194892
Real-world Effectiveness (RWE) and Adverse Events with Sofosbuvir plus Ribavirin (SOF+RBV) Based Therapies in Chronic Hepatitis C Genotype 3 (CHC GT 3) Patients in Asia- A Systematic Review of 8 Studies and 3510 Patient
AASLD LiverLearning®, Bin Wei, 195148
Rab1a Binds to and Recruits the Minus-end-directed Kinesin, KifC1, to Early Endocytic Vesicles
AASLD LiverLearning®, Allan Wolkoff, 194893
Hepatitis C treatment with Simeprevir and Sofosbuvir in low socioeconomic population in a Federally Qualified Health Center [FQHC]
AASLD LiverLearning®, Jordan Nicquette, 195149
The Cytoskeletal Protein β-Actin Mediates T Cell Apoptosis during Acute Liver Allograft Rejection in a Rat Model
AASLD LiverLearning®, Genshu Wang, 194894
Care Cascade for Persons with Chronic Hepatitis C Infection: A Single Center Data from Mongolia
AASLD LiverLearning®, Tserenchime Sarantuya, 195150
Direct Acting Antiviral Therapy is Associated with Shorter Time to HCC Recurrence but not Increased Risk of Recurrence
AASLD LiverLearning®, Amit Singal, 194908
Are we done with the immunohistochemical classification of hepatocellular adenoma?
AASLD LiverLearning®, Christine Sempoux, 195164
Hepatocellular Carcinoma Surveillance using Ultrasound and AFP Improves Early Detection and Survival in Patients with Cirrhosis
AASLD LiverLearning®, Nicole Rich, 194909
Diagnosis of asymptomatic hepatocellular carcinoma by screening offers survival advantages compared to the symptom driven diagnosis
AASLD LiverLearning®, Jiyu Kim, 195165
Natural course and clinical implications of hypovascular lesions on dynamic CT and/or Gd-EOB-DTPA-enhanced MRI detected during the diagnosis of hepatocellular carcinoma
AASLD LiverLearning®, Hiroshi Imamura, 194910
Serum Wisteria floribunda agglutinin-positive sialylated Mucin 1 as a meaningful prognostic biomarker after hepatic resection for HCV-positive patients with hepatocellular carcinoma
AASLD LiverLearning®, Shuhei Hige, 195166
No evidence of hepatitis B virus reactivation among liver transplant recipients treated with interferon-free regimens for hepatitis C virus recurrence (ANRS CO23 CUPILT Cohort)
AASLD LiverLearning®, Jean-Charles Duclos-Vallee, 195179
Predictive microenvironment factors in hepatic tissue are key in the development of de novo occurrence or recurrent HCCs after DAAs
AASLD LiverLearning®, Luca Marzi, 194924
Molecular Characterization of Three Human Hepatitis E Virus (HEV) isolated in France
AASLD LiverLearning®, Ka-Cheung Luk, 195180
HCC-derived lncRNA CRNDE Inhibits T Lymphocyte Activation and Impairs Host Immunity Leading to Immune Evasion and HCC Progression
AASLD LiverLearning®, Jinqiang Zhang, 194925
Longitudinal Analysis of Hepatitis E Virus (HEV) in a U.S. Cohort of HIV-Infected Liver and Kidney Transplant Recipients
AASLD LiverLearning®, Kenneth Sherman, 195181
Clusterin and its’ related NR index could serve as an early predictor of sorafenib response.
AASLD LiverLearning®, Satoshi Narahara, 194926
Direct-Acting Antiviral Regimens are Safe and Effective in the Treatment of Hepatitis C in Simultaneous Liver-Kidney Transplant Recipients
AASLD LiverLearning®, Anu Nookala, 195182
Shock Livers and the Opioid Epidemic: An Underutilized Resource in a Growing Population of Donors
AASLD LiverLearning®, Melissa Gadsden, 195195
Transarterial chemoembolization shows no superiority to bland embolization as the adjuvant therapy after curative hepatectomy for hepatocellular carcinoma: a retrospective cohort study
AASLD LiverLearning®, Lei Zhao, 194940
Implementation of Share 35 Policy has Improved Survival following Liver Transplantation
AASLD LiverLearning®, George Cholankeril, 195196
Tumor burden improves prognosis prediction for patients with terminal hepatocellular carcinoma: a nomogram study
AASLD LiverLearning®, Chia-Yang Hsu, 194941
Outcomes Of Liver Transplantation After Downstaging For Hepatocellular Carcinoma Beyond Milan Criteria
AASLD LiverLearning®, Bhavana Bhagya Rao, 195197
Application of the Albumin Bilirubin (ALBI) Grade improves the prognostic ability of the Barcelona Clinic Liver Cancer (BCLC) Staging system and helps to guide therapy.
AASLD LiverLearning®, Prem Thurairajah, 194942
Stent or no stent? A randomized controlled trial comparing the incidence of biliary complications after liver transplantation, interim analysis
AASLD LiverLearning®, Jennifer Haglund, 195198
Impact of “Rescue Allocated” Livers On Outcomes After Liver Transplantation: A Propensity Score Matching Analysis.
AASLD LiverLearning®, Mara Disabato, 195211
Phase 3 biomarker study for HCC surveillance using AFP, AFP-L3 and DCP: A prospective collection with retrospective blinded evaluation
AASLD LiverLearning®, Hashem El-Serag, 194956
Significance of surgical margin in patients with single hepatocellular carcinoma undergoing curative hepatic resection: an analysis using nationwide survey data in Japan
AASLD LiverLearning®, Taku Aoki, 195212
Serum Biomarkers Improve Prognostic Ability of BCLC Staging System
AASLD LiverLearning®, Saroja Bangaru, 194957
Living Related Liver Transplantation (LRLT) for Progressive Familial Intrahepatic Cholestasis Type III (PFIC III) Children: A Single Center Experience
AASLD LiverLearning®, Tawhida Abdel Ghaffar, 195213
Impact of Hepatocellular Carcinoma (HCC) and Tumor Treatment on Sustained Virologic Response (SVR) Rates with Direct-Acting Antiviral (DAA) Therapy for Hepatitis C: HCV-TARGET Results
AASLD LiverLearning®, Kavita Radhakrishnan, 194958
Preoperative erythropoietin treatment improves overall survival after major hepatic resection in cirrhotic rat models
AASLD LiverLearning®, Sukwon Suh, 195214
Long-term clinical outcomes evaluation of everolimus in liver transplant patients with autoimmune liver diseases: Pooled analysis from the H2304 and PROTECT trials
AASLD LiverLearning®, John Fung, 195227
A Novel Prognostic Algorithm for Patients with NAFLD-related Hepatocellular Carcinoma: A Nationwide Data-mining Analysis by Japan Study Group of NAFLD
AASLD LiverLearning®, Takumi Kawaguchi, 194972
Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Non-alcoholic Steatohepatitis (NASH) Cirrhosis: Twenty-Two Years Data from the Scientific Registry of Transplant Recipients (SRTR)
AASLD LiverLearning®, Zobair Younossi, 195228
Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy
AASLD LiverLearning®, Atsushi Ono, 194973
Recurrence-Free Survival in Liver Transplant Recipients with Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Results from the US Multicenter HCC Transplant Consortium
AASLD LiverLearning®, Elizabeth Verna, 195229
Impact of HIV and Chronic HCV Status on Advanced HCC Stage in Veterans
AASLD LiverLearning®, Jessie Torgersen, 194974
Safety and Efficacy Profile of Everolimus With Reduced Tacrolimus in Living Donor Liver Transplant Recipients - 12-month Results From the Pivotal H2307 Study
AASLD LiverLearning®, Daniel Maluf, 195230
Severe Hepatic Encephalopathy is an Independent Predictor of Waitlist Mortality in Patients with High MELD
AASLD LiverLearning®, George Cholankeril, 195243
Incidentally detected Hepato-cellular carcinoma: Silent, larger, aggresive !!
AASLD LiverLearning®, D. Reddy, 194988
Bile Acid Metabolites in Urine: A Promising Novel Biomarker Predicting Renal Recovery After Liver Transplantation
AASLD LiverLearning®, Ashwani Singal, 195244
Conditional survival estimates improve over time for patients with hepatocellular carcinoma: An analysis for nationwide Korea cancer registry database
AASLD LiverLearning®, Jae Seung Lee, 194989
Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Candidates
AASLD LiverLearning®, Kymberly Watt, 195245
Assessing Hong Kong Liver Cancer classification in a Western cohort: results from South America
AASLD LiverLearning®, Mario Alvares-da-Silva, 194990
Perioperative Glucose Management and Outcomes in Liver Transplant Recipients: A Qualitative Systematic Review
AASLD LiverLearning®, Sarah Lieber, 195246
Post-Transplant Complications in Obese Liver Transplant Recipients: A Systematic Review and Meta-Analysis
AASLD LiverLearning®, Faisal Kamal, 195259
Demographic and Clinical Outcomes of Patients with Hepatocellular Carcinoma(HCC) NOS compared with Clear Cell Hepatocellular Carcinoma(HCC): A United States Population Based Analysis (SEER 1973-2013)
AASLD LiverLearning®, Manu Kaushik, 195004
Impact of Nutritional Status and Vitamin Deficiencies on Pre- and Post-Liver Transplant Rates of Hospitalization or Death
AASLD LiverLearning®, Andree Koop, 195260
Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA)
AASLD LiverLearning®, Enrico Gringeri, 195005
Efficacy and Safety of Covered Self-Expandable Metal Stents versus Multiple Plastic Stents for the Treatment of Anastomotic Biliary Strictures in Liver Transplant Patients: A Meta-Analysis
AASLD LiverLearning®, Harika Balagoni, 195261
The incidence of Denovo HCC or aggressive recurrence of HCC in patients with HCV infection receiving DAA therapy.
AASLD LiverLearning®, Hany Elbeshbeshy, 195006
Strain Analysis in Preoperative Echocardiograms Does Not Predict Acute Heart Failure after Liver Transplantation
AASLD LiverLearning®, Lauren Grinspan, 195262
Predictors of Hospital Readmission Within 90 Days Following Liver Transplantation: A Single Centre Experience
AASLD LiverLearning®, Anouar Teriaky, 195275
The role of IL-21 in the process of HBsAg clearance in the invitro and in vivo study
AASLD LiverLearning®, Libo Tang, 195020
Pregnancy Outcomes and Reproductive Health After Liver Transplantation
AASLD LiverLearning®, Christina Lindenmeyer, 195276
HBV-specific T cell immunity in inactive carrier patients is independent of Hepatitis B surface antigen load.
AASLD LiverLearning®, Upkar Gill, 195021
Pediatric Acute Liver Failure and Acute Hepatitis of Indeterminate Cause Treated with Steroids
AASLD LiverLearning®, Catherine Chapin, 195277
Discovery of A Highly Potent and Selective Capsid Assembly Inhibitor (WX-066) For the Treatment of Chronic HBV Infection
AASLD LiverLearning®, Haiying He, 195022
PDCD1 methylation status predicts Hepatitis B Surface antigen seroclearance in HBV reactivation
AASLD LiverLearning®, MOJAHIDUL ISLAM, 195036
MX1 variants differentially regulate HBV replication
AASLD LiverLearning®, Wenyu Lin, 195037
Rab5B determines HBV release pathways by promoting transport of LHBs from ER to MVB
AASLD LiverLearning®, Jun Inoue, 195038
The role of ulinastatin in the treatment of liver failure
AASLD LiverLearning®, Bo Wei, 194796
Fusion HBx from HBV integrant might be implicated in hepatocarcinogenesis through dysregulation of ER stress response
AASLD LiverLearning®, Ryosuke Muroyama, 195052
Drug- Induced Acute Liver Failure in 128 Patients Including Children: Implicated Drugs, Outcome, Predictors of Mortality - Results From a Single-Center Drug-induced Liver Injury Registry
AASLD LiverLearning®, Harshad Devarbhavi, 194797
Change in T cell cytokines and Tregs as markers of HBV reactivation in patients with hepatocellular carcinoma
AASLD LiverLearning®, Sung Won Lee, 195053
Multi-platform metabonomics reveals a distinct metabolic phenotype of acute-on-chronic liver failure
AASLD LiverLearning®, Rabiya Zia, 194798
Clinics features of HBeAg-positive treatment-naïve chronic hepatitis B patients with precore and/or basal core promoter mutations
AASLD LiverLearning®, Li-Bo Yan, 195054
Impact of plasmapheresis on outcomes in patients with Acute liver Failure fulfilling King’s College Criteria
AASLD LiverLearning®, Akash Shukla, 194799
Multicenter Survey for Patients with Acute-on-Chronic Liver Failure in Japan
AASLD LiverLearning®, Hayato Uemura, 194812
Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection: An Integrated Analysis of Data from 11 Phase 2/3 Trials
AASLD LiverLearning®, Lai Wei, 195068
Direct comparison of two mouse models of Type A hepatic encephalopathy.
AASLD LiverLearning®, Stephanie Grant, 194813
Modification of the MELD Score with Serological Fibrosis Markers Reflecting Extracellular Matrix Remodeling Improves Prediction of Outcomes in Non-acetaminophen-associated Acute Liver Failure
AASLD LiverLearning®, Po-Sung Chu, 194814
Efficacy and safety of treatment with direct acting antiviral(s) in Chronic Hepatitis C (CHC) patients with compensated advanced liver disease and signs of portal hypertension. HERACLIS: a Hellenic multicenter real-life cohort clinical study
AASLD LiverLearning®, Ioannis Vlachogiannakos, 195070